HealthQuill MASH
Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without worsening the condition.
Drugs Health Pharma

Novo Nordisk’s weight loss drug reduces live scarring in end-stage trial

Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.

Read More
US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary goals of efficacy and safety in patients, according to a company statement.
Drugs Health Pharma

Akero Therapeutics says mid-stage trials on drug for fatty liver disease positive

HQ Team March 4, 2024: US-based Akero Therapeutics, Inc., announced its mid-trial of a drug to treat fatty liver disease met its primary.

Read More